Marc Andre Marcotte
Managing Director & Head of Research @ Sectoral Asset Management
Marc Andre Marcotte is a Series B investor at Sectoral Asset Management focused on Health Care and Medical. Mr. Marcotte joined Sectoral in 2006. He is responsible for overseeing the investment research activities at Sectoral. He is also responsible for the coverage of Medical Technology companies. In September 2013, Mr. Marcotte was nominated a Managing Director of Sectoral Asset Management and participates in the Executive Committee of the firm.Prior to joining Sectoral, he worked at CryoCath Technologies, a company specializing in the development of products to treat cardiovascular diseases, where he was the Director of Quality. Before this, he worked with Medtronic AVE in Vancouver as an engineer on angioplasty catheters and stents. He has over eight years of experience in the development of Medical Devices.Mr. Marcotte graduated from Sherbrooke University in 1997 with a Bachelor of Engineering and completed a Master of Business Administration at HEC Montreal in 2003. He obtained his CFA charter in 2010.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Marc Andre Marcotte invests in
Stages Marc Andre Marcotte invests in
Countries Marc Andre Marcotte invests in
Investment Focus
Industry
- Health Care 5 (56%)
- Medical 3 (33%)
- Medical Device 3 (33%)
- Wellness 1 (11%)
- Life Science 1 (11%)
Stage
- Series B 3 (33%)
- Series C 2 (22%)
- Series A 1 (11%)
- Series D 1 (11%)
- Funding Round 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SecondWave Systems
|
SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppressesneural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders. | Series A / Oct 22, 2025 | |
Iantrek
|
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M / Series C / Aug 20, 2025 | |
Neuros Medical
|
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M / Series D / Jul 09, 2025 | |
CurvaFix
|
CurvaFix is an emerging medical device company based in the Seattle area. We are developing a novel solution for an unmet need in orthopedic trauma. | $39M / Series C / Jul 14, 2023 | |
|
Iantrek
|
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $23M / Series B / Aug 30, 2022 | |
Magnolia Medical Technologies
|
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | Feb 16, 2022 | |
|
Magnolia Medical Technologies
|
Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests. It has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’sintellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending.It was incorporated in 2011 and is based in Seattle, Washington. | $46M / Private Equity / Feb 16, 2022 | |
|
Neuros Medical
|
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $38.5M / Series B / Jan 07, 2021 | |
|
CurvaFix
|
CurvaFix is an emerging medical device company based in the Seattle area. We are developing a novel solution for an unmet need in orthopedic trauma. | $10.7M / Series B / Jul 21, 2020 |
Co-Investors
About Sectoral Asset Management
Sectoral Asset Management Inc. is an industry-leading specialist in managing global investment portfolios in the healthcare sector. Sectoral maintains offices in Montreal and Geneva and is a proud member of the State Street Global Alliance. They currently manage approximately US $4.0 billion in assets.
Sectoral Asset Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Marc Andre Marcotte
Managing Director & Head of Research
|
|||
Alex Bernal
IT Manager
|
|||
Dimo Vodenitcharov
Network Administrator
|
|||
Guillaume Aquin
Senior Manager Trading & Operations
|
|||
Justin Gelinas
Operations Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Marc Andre Marcotte invest in?
Marc Andre Marcotte invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Marc Andre Marcotte last invest?
The most recent investment recorded for Marc Andre Marcotte closed in Oct 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
